Market research
TECX Tectonic Therapeutic, Inc.
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 713M
- P/E ratio
- Not available
- Analyst target
- 77.5556
- Dividend yield
- Not available
- Beta
- 0.22
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US8789721086
- Market cap
- 713M
- P/E ratio
- Not available
- Analyst target
- 77.5556
- Dividend yield
- Not available
- Beta
- 0.22
About
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the TECX discussion.
No comments yet
Start a focused discussion about TECX.